Status epilepticus (SE) is a neurological emergency associated with a high mortality rate. Collaborative efforts have been made to establish standardized definitions, classifications, and treatment protocols to improve management and reduce mortality. In 2015, the International League Against Epilepsy (ILAE) developed a new definition and classification system for SE, taking into account the pathophysiology of SE and setting time points for treatment decision-making, while considering the variability in seizure semiology. Timely identification of the underlying cause of SE would facilitate more targeted treatment, as almost half of all SE cases require specific therapy for the underlying cause in addition to providing symptomatic treatment. A stepwise algorithm for seizure management is proposed, with the initial stage involving the administration of benzodiazepines (BZD), followed by the use of non-sedating anti-seizure medications (ASM) as the second line of treatment. The decision to resort to therapeutic coma is made on a case-by-case basis, as most invasive treatments may not always be the best approach. This comprehensive review provides an overview of SE and its definition, pathophysiology, diagnostic challenges, and recent treatment advances.
OBJECTIVES:To evaluate the diagnostic performance of iodine density map (IDM) using dual-energy CT (DECT) in differentiating colorectal cancer from benign colorectal wall thickening. MATERIAL AND METHODS:This IRB-approved dual-center retrospective exploratory study included 71 consecutive patients with colorectal wall thickening due to tumoral or non-tumoral origin, confirmed by colonoscopy and assessed with DECT. Thirty-eight had pathology-proven colorectal adenocarcinoma, and 33 had non-neoplastic thickening (inflammation, physiologic collapse, or post-radiotherapy change). Iodine density values were measured from regions of interest on three consecutive CT slices on portal venous phase, normalized to aortic iodine concentration. Diagnostic performance was determined by ROC analysis, and inter-reader agreement was evaluated with intraclass correlation coefficients (ICC) and limits of agreement (LOA). RESULTS:Mean IDM value was significantly higher in tumors than in benign thickening (2.31 ± 0.42 vs 1.43 ± 0.24 mg/mL; p < 0.001). Mean normalized iodine density map (NIDM) value was likewise elevated in tumors (0.46 ± 0.10 vs 0.31 ± 0.07; p < 0.001). ROC analysis demonstrated excellent performance for both IDM (AUC 0.98; optimal cutoff 1.72 mg/mL; sensitivity 92.1%, specificity 90.9%, NPV 90.9%) and NIDM (AUC 0.88; cutoff 0.35; sensitivity 92.1%, specificity 69.7%, NPV 88.7%). There was no significant difference between the inflammatory and collapsed-wall subgroups. Inter-reader agreement was excellent (ICC: 0.93 for IDM; 0.92 for NIDM). CONCLUSION:IDM and NIDM on DECT provide robust, reproducible markers that differentiate colorectal carcinoma from benign wall thickening with high diagnostic accuracy. These quantitative parameters may improve diagnostic confidence and reduce unnecessary colonoscopies, supporting their integration into colorectal cancer evaluation.
Importance:Impairment of working memory (WM), which relies on distributed cortical and subcortical structures, including cerebello-striatal pathways, is a core contributor to functional decline in patients with mild cognitive impairment (MCI) and dementia. Because the striatum is affected early in dementia, whereas the cerebellum remains relatively preserved, the cerebellum may offer support for maintaining striatal function in neurodegenerative diseases. Objective:To evaluate whether sequential cerebellar transcranial magnetic stimulation (TMS) and striatal transcranial temporal interference stimulation (tTIS) enhances WM in patients with MCI, especially those with early striatal degeneration, like MCI with Lewy bodies (MCI-LB). Design, Setting, and Participants:This randomized, quadruple-blind, placebo-controlled, crossover trial was conducted from August 2023 to October 2024 at 1 site in Switzerland and 1 in Czech Republic. Participants included individuals with MCI-LB or amnestic MCI (aMCI) and age-matched healthy controls (HCs). Intervention:Three pseudorandomized single stimulation sessions: (1) cerebellar TMS followed by striatal tTIS, (2) control TMS followed by striatal tTIS, and (3) an active control combining control TMS with control striatal tTIS. Main Outcomes and Measures:The primary outcomes were changes in accuracy and correct answer reaction times in a visual WM task with varying memory loads and distractors. Modulators included resting-state functional connectivity and gray-matter volume in WM-related regions. Linear mixed-effects models were used to examine the main effects of stimulation condition on accuracy and reaction times. Results:Forty-one patients with MCI, including 21 with MCI-LB (16 female [76%]; mean [SD] age, 71.05 [6.84] years) and 20 with aMCI (11 female [55%]; mean [SD] age, 72.30 [7.50] years), and 20 HCs (10 female [50%]; mean [SD] age, 69.5 [4.42] years) were analyzed. In patients with MCI-LB, cerebellar TMS plus striatal tTIS increased accuracy in distractor trials compared with the active control (control TMS plus control tTIS, P < .001; d = -0.77) and striatal tTIS alone (control TMS plus striatal tTIS, P = .004; d = -0.60). Greater accuracy gains were associated with lower putaminal connectivity (r = -0.66; P = .03). In patients with aMCI, cerebellar volumes showed associations with task performance in both distractor trials (cerebellar TMS plus striatal tTIS, R2 = 0.27; P = .02) and high-load trials (control TMS plus striatal tTIS, R2 = 0.24; P = .03), and larger volumes were associated with faster responses; however, significant behavioral differences between active and control stimulation conditions were not observed. No serious adverse events occurred. Conclusions and Relevance:Synergistic dual-target cerebellar TMS and striatal tTIS improved WM in MCI-LB, particularly in patients with lower striatal connectivity, suggesting dual-targeted neuromodulation as a potential therapeutic avenue in neurodegenerative disorders. Trial Registration:ClinicalTrials.gov Identifier: NCT07090681.
BackgroundMinor hallucinations (MH) affect 30-60% of patients with Parkinson's disease (PD), and are considered precursors to structured visual hallucinations and cognitive decline. While the link between structured visual hallucinations and dementia is well established, the neuropsychological correlates of MH in PD remain unclear; most studies finding no significant cognitive differences between patients with MH and those without any hallucinations.ObjectivesPresence hallucinations (PH) being among the most prevalent MH in PD, we used a robotic procedure delivering somatomotor conflicts inducing PH experimentally to investigate whether sensitivity to such robot-induced PH aids in detecting cognitive differences between patients with MH and without hallucinations.Methods31 PD patients with MH (PD-MH) and 37 without hallucinations (PD-nH) underwent neuropsychological assessment and the robotic procedure inducing PH. The sensitivity to report robot-induced PH was analyzed in relation to cognitive performance in neuropsychological tests.ResultsPD-MH patients reported more robot-induced PH than PD-nH patients, supporting previous findings. While both groups showed comparable performance in neuropsychological testing, we found a significant association between increased sensitivity to the PH-induction and poorer performance in frontal subcortical cognitive functions, in PD-MH patients, but not in PD-nH patients.ConclusionsThese findings demonstrate that sensitivity to robot-induced PH reveals a previously undetected link between MH and frontal subcortical cognitive deficits in PD, pointing to shared underlying mechanisms between executive dysfunction and somatomotor processes involved in MH. This approach offers a novel and clinically valuable means of identifying early cognitive vulnerability that assessments relying only on standard testing may overlook.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a subset occurring in the context of hereditary cancer predisposition. BRIP1 is involved in homologous recombination repair, and pathogenic germline variants are established risk factors for ovarian cancer. However, its role in pancreatic cancer susceptibility and treatment response remains poorly defined. We report PDAC in a father and son whose tumors independently harbored the same BRIP1 p.K159E variant of uncertain significance (VUS), with clinical features suggestive of potential homologous recombination deficiency (HRD). A father and son developed PDAC at 70 and 39 years, respectively. Tumor profiling identified the same BRIP1 p.K159E VUS in both, alongside canonical PDAC-associated alterations. Germline testing was not performed. Both patients showed clinically meaningful sensitivity to platinum-based chemotherapy. The father achieved a partial response to FOLFIRINOX for early metastatic recurrence but subsequently deteriorated and died within one year of diagnosis. The son achieved prolonged disease control with platinum-based chemotherapy and multimodal treatment, including surgery and local therapies for oligoprogression, surviving approximately five years. Maintenance olaparib was briefly administered but discontinued because of hematological toxicity and subsequent disease progression. The occurrence of PDAC in two first-degree relatives, including early-onset disease in the son, together with the same BRIP1 p.K159E VUS in both tumors, represents an unusual familial and molecular observation. Although germline status and pathogenicity cannot be established, the shared alteration and platinum sensitivity raise the hypothesis that this BRIP1 variant may warrant further investigation in the context of homologous recombination repair. However, platinum sensitivity alone cannot be considered evidence of homologous recombination deficiency. The uncertain benefit from PARP inhibition further highlights the limitations of inferring therapeutic actionability from an individual HRR gene VUS. Further germline and functional investigation of BRIP1 alterations in PDAC is warranted.